Greenway acquires patient engagement solution PeopleLYNK

Laura Pedulli | | Health Exec | EMR/EHR

Greenway Medical Technologies, a Ga.-based IT company, has acquired PeopleLYNK, a patient engagement solution. Terms of the transaction were not disclosed.

By purchasing PeopleLYNK, Greenway aims to extend its patient engagement services to foster improved population health and patient satisfaction—major goals of Meaningul Use Stage 2.

PeopleLYNK promotes patient engagement in cooperation with PrimeSUITE, Greenway’s integrated practice management and EHR solution. Based on criteria in PrimeSUITE established by the provider organization, PeopleLYNK automates certain interactions with patients, including reminders, lab results, prescription notifications, clinical alerts and other communications.

"Over time" all Greenway customers will benefit from PeopleLYN’s capabilities, according to the announcement.

 

Laura Pedulli

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.